Dupixent
Type 2 inflammation control for moderate to severe atopic dermatitis.
Dupixent (dupilumab) blocks IL-4 and IL-13 signalling, the pathway responsible for the itch, barrier failure and relapse cycle of atopic dermatitis. It is not an immunosuppressant, so no routine blood monitoring is required.
- Injection
- Route
- 2 weekly
- Interval
- 2–4 wks
- First results
- IL-4 / IL-13
- Target
- Loading dose
- Fortnightly injection
- Emollient protocol
- Flare action plan
Diagnosed first, treated second.
Treatment addresses the mechanism while barrier care continues alongside: emollients, trigger management and short topical courses. Itch usually settles before the skin looks clear, which is often the change patients notice first.
- 01Loading dose
- 02Fortnightly injection
- 03Emollient protocol
- 04Flare action plan
- 05Ocular monitoring
- Moderate to severe eczema despite topicals
- Sleep loss from persistent itch
- Repeated steroid or ciclosporin courses
- Widespread or facial involvement
- Adults and eligible children
How the treatment works
A sequence, not a single appointment — each step informs the next.
- 01
Severity mapping
Body surface scoring, itch and sleep assessment, and review of prior topical and systemic therapy.
- 02
Baseline work
Screening bloodwork, parasite and infection review, and an ocular history.
- 03
Loading dose
An initial double dose, then fortnightly injections taught for home administration.
- 04
Barrier programme
Emollient and bathing protocol, flare plan and review at four, twelve and twenty-four weeks.
Results measured, not promised.
What to expect
- 01Rapid reduction in itch, often within two weeks
- 02Improved sleep and daytime concentration
- 03Fewer flares and infected eczema episodes
- 04Reduced need for topical steroids
- 05Restored barrier and skin comfort
Begin with a diagnosis,
not a guess.
Share a few details and the clinic will reply with available consultation times for dupixent — one-to-one with Dr. Arely.
- Response
- Within 24 hours
- Consultation
- One-to-one, 45 min
- Assessment
- Trichoscopy included
- Location
- Dr. Arely Clinic
Frequently asked
No. It targets two specific signalling molecules, so routine blood monitoring is not needed.
Often within the first two weeks, ahead of visible clearance of the skin.
Injection-site reactions and conjunctivitis are the most frequent; both are usually manageable.
Yes. Emollients remain the foundation of barrier repair throughout treatment.